The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 25, 2023

Filed:

Nov. 10, 2017
Applicant:

Wisconsin Alumni Research Foundation, Madison, WI (US);

Inventors:

Jamey Weichert, Sun Prairie, WI (US);

Paul Sondel, Madison, WI (US);

Ravi Patel, Madison, WI (US);

Zachary Morris, Madison, WI (US);

Peter Carlson, Madison, WI (US);

Reinier Hernandez, Madison, WI (US);

Joseph Grudzinski, Madison, WI (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 51/04 (2006.01); A61P 35/00 (2006.01); A61K 41/00 (2020.01); A61K 51/10 (2006.01); A61K 39/395 (2006.01); A61P 35/04 (2006.01); A61K 38/20 (2006.01); C07K 16/30 (2006.01); C07K 14/52 (2006.01); A61P 37/04 (2006.01); C07K 16/28 (2006.01); A61N 5/00 (2006.01); A61N 5/10 (2006.01); A61K 9/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 51/0485 (2013.01); A61K 38/2013 (2013.01); A61K 39/39541 (2013.01); A61K 39/39558 (2013.01); A61K 41/0038 (2013.01); A61K 51/0408 (2013.01); A61K 51/0489 (2013.01); A61K 51/0497 (2013.01); A61K 51/1045 (2013.01); A61N 5/00 (2013.01); A61N 5/1001 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); A61P 37/04 (2018.01); C07K 14/52 (2013.01); C07K 16/2818 (2013.01); C07K 16/3084 (2013.01); A61K 9/0019 (2013.01); A61K 2039/505 (2013.01); A61N 2005/1021 (2013.01); C07K 2319/35 (2013.01);
Abstract

The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid ether metal chelate, a radiohalogenated phospholipid ether, or other targeted radiotherapy (TRT) agent that is differentially retained within malignant solid tumor tissue, and either (a) performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or (b) performing immunotherapy in the subject by systemically administering to the subject an immunostimulatory agent, such as an immune checkpoint inhibitor. In a non-limiting example, the radioactive phospholipid ether metal chelate or radiohalogenated phospholipid ether has the formula: wherein Rcomprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half-life of greater than 6 hours and less than 30 days, or wherein Rcomprises a radioactive halogen isotope. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and Ris —N(CH).


Find Patent Forward Citations

Loading…